Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity

Molecular Psychiatry

Volumn 19, Issue 10, 2014, Pages 1143-1149

  Hammer, C ^a   Stepniak, B ^a   Schneider, A ^b,c,d   Papiol, S ^a,c   Tantra, M ^a,c   Begemann, M ^a   Siren A L ^e   Pardo, L A ^a   Sperling, S ^a   Mohd Jofrry, S ^a   Gurvich, A ^a   Jensen, N ^a   Ostmeier, K ^a   Luhder F ^b   Probst, C ^f   Martens, H ^g   Gillis, M ^h   Saher, G ^a   Assogna, F ⁱ   Spalletta, G ⁱ   Stocker W ^f   Schulz, T F ^h   Nave, K A ^a,c   Ehrenreich, H ^a,c   more..

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c Deutsche Forschungsgemeinschaft   (Germany)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f Institute of Experimental Immunology   (Germany)

^g SYNAPTIC SYSTEMS GMBH   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

APOE; ApoE null mutant mice; Autoimmunity; GWAS; Influenza; NFIA

Indexed keywords

APOLIPOPROTEIN E; AUTOANTIBODY; HETERODIMER; IMMUNOGLOBULIN A; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; CONTROLLED STUDY; ENDOCYTOSIS; FEMALE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INFLUENZA A; INFLUENZA B; MALE; MENTAL DISEASE; MOOD DISORDER; MOUSE; NERVOUS SYSTEM INJURY; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROPREVALENCE; SEX DIFFERENCE; ANIMAL; BLOOD; BRAIN CORTEX; C57BL MOUSE; GENETIC ASSOCIATION; GENETICS; IMMUNOLOGY; INFLUENZA; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; NERVE CELL; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANIMALS; APOLIPOPROTEINS E; AUTOANTIBODIES; BLOOD-BRAIN BARRIER; CEREBRAL CORTEX; ENDOCYTOSIS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INFLUENZA, HUMAN; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MOOD DISORDERS; NEURONS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84920889270     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.110     Document Type: Article

References (45)

1. Li F, Tsien JZ. Memory and the NMDA receptors. N Engl J Med 2009; 361: 302-303.
2. Lau CG, Zukin RS. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci 2007; 8: 413-426.
3. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007; 27: 11496-11500.
4. Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36.
5. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-1098.
6. Masdeu JC, Gonzalez-Pinto A, Matute C, Ruiz De Azua S, Palomino A, De Leon J et al. Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. Am J Psychiatry 2012; 169: 1120-1121.
7. Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P et al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011; 258: 686-688.
8. Tsutsui K, Kanbayashi T, Tanaka K, Boku S, Ito W, Tokunaga J et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry 2012; 12: 37.
9. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74.
10. Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157-165.
11. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010; 30: 5866-5875.
12. Pruss H, Holtje M, Maier N, Gomez A, Buchert R, Harms L et al. IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology 2012; 78: 1743-1753.
13. Choe CU, Karamatskos E, Schattling B, Leypoldt F, Liuzzi G, Gerloff C et al. A clinical and neurobiological case of IgM NMDA receptor antibody associated encephalitis mimicking bipolar disorder. Psychiatry Res 2012; 208: 194-196.
14. Pruss H, Finke C, Holtje M, Hofmann J, Klingbeil C, Probst C et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012; 72: 902-911.
15. Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein HG, Vielhaber S et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013; 70: 271-278.
16. Begemann M, Grube S, Papiol S, Malzahn D, Krampe H, Ribbe K et al. Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. Arch Gen Psychiatry 2010; 67: 879-888.
17. Ribbe K, Friedrichs H, Begemann M, Grube S, Papiol S, Kastner A et al. The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients. BMC Psychiatry 2010; 10: 91.
18. Wandinger KP, Saschenbrecker S, Stoecker W, Dalmau J. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol 2011; 231: 86-91.
19. Toyka KV, Brachman DB, Pestronk A, Kao I. Myasthenia gravis: passive transfer from man to mouse. Science 1975; 190: 397-399.
20. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 1992; 89: 4471-4475.
21. Radyushkin K, El-Kordi A, Boretius S, Castaneda S, Ronnenberg A, Reim K et al. Complexin2 null mutation requires a 'second hit' for induction of phenotypic changes relevant to schizophrenia. Genes Brain Behav 2010; 9: 592-602.
22. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
23. Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD. Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice. Exp Neurol 2001; 169: 13-22.
24. Saher G, Rudolphi F, Corthals K, Ruhwedel T, Schmidt KF, Lowel S et al. Therapy of Pelizaeus-Merzbacher disease in mice by feeding a cholesterol-enriched diet. Nat Med 2012; 18: 1130-1135.
25. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012; 485: 512-516.
26. Shlosberg D, Benifla M, Kaufer D, Friedman A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol 2010; 6: 393-403.
27. Baburamani AA, Ek CJ, Walker DW, Castillo-Melendez M. Vulnerability of the developing brain to hypoxic-ischemic damage: contribution of the cerebral vasculature to injury and repair? Front Physiol 2012; 3: 424.
28. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Hum Genet 2012; 90: 7-24.
29. Zheng S, Eacker SM, Hong SJ, Gronostajski RM, Dawson TM, Dawson VL. NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. J Clin Invest 2010; 120: 2446-2456.
30. Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol 2010; 87: 385-395.
31. Ascherio A, Munger KL, Lunemann JD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012; 8: 602-612.
32. Dale RC, Irani SR, Brilot F, Pillai S, Webster R, Gill D et al. N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol 2009; 66: 704-709.
33. Tan A, Shuey N, Bladin C. A modern perspective on the differential diagnosis between encephalitis lethargica or anti-NMDA-receptor encephalitis. J Clin Neurosci 2010; 17: 1204-1206.
34. Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 2001; 184: 101-122.
35. Ek CJ, Dziegielewska KM, Habgood MD, Saunders NR. Barriers in the developing brain and Neurotoxicology. Neurotoxicology 2012; 33: 586-604.
36. Grzeda E, Wisniewska RJ, Wisniewski K. Effect of an NMDA receptor agonist on T-maze and passive avoidance test in 12-week streptozotocin-induced diabetic rats. Pharmacol Rep 2007; 59: 656-663.
37. Sharp FR, Hendren RL. Psychosis: atypical limbic epilepsy versus limbic hyperexcitability with onset at puberty? Epilepsy Behav 2007; 10: 515-520.
38. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
39. Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J. Afferent facilitation of corticomotor responses is increased by IgGs of patients with NMDA-receptor antibodies. J Neurol 2011; 258: 27-33.
40. Bechter K, Reiber H, Herzog S, Fuchs D, Tumani H, Maxeiner HG. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res 2010; 44: 321-330.
41. Doria A, Canova M, Tonon M, Zen M, Rampudda E, Bassi N et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 2008; 8: 24-28.
42. Randone SB, Guiducci S, Cerinic MM. Systemic sclerosis and infections. Autoimmun Rev 2008; 8: 36-40.
43. Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. JNeurosci2005; 25: 3312-3322.
44. Larrauri A, de Mateo S. Characterisation of swabbing for virological analysis in the Spanish Influenza Sentinel Surveillance System during four influenza seasons in the period 2002-2006. Euro Surveill 2007; 12: E5-E6.
45. Avitsur R, Mays JW, Sheridan JF. Sex differences in the response to influenza virus infection: modulation by stress. Horm Behav 2011; 59: 257-264.